IciCLLe -Assessment of the Mechanism of Action of Ibrutinib
Research type
Research Study
Full title
IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.
IRAS ID
136775
Contact name
Peter Hillmen
Contact email
Eudract number
2012-003608-11
ISRCTN Number
N/A
Research summary
The aims of this study are to confirm i) how ibrutinib works within the body and ii) how patients disease responses to ibrutinib treatment in two cohorts; Patients that have not previously been treated for their CLL and Patient that have been treated for CLL but their disease has returned or their treatment is no longer working.
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
14/YH/0034
Date of REC Opinion
20 Feb 2014
REC opinion
Favourable Opinion